Clinical trials: sponsored by Arrowhead Pharmaceuticals

Non-alcoholic Steatohepatitis

Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH

• Completed
• Age: 19 to 65 years
• Phase 1/2
• Injection or infusion
• Results posted

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of single and multiple doses of ARO-HSD in healthy adult volunteers and in patients with NASH or suspected NASH.

Trial name

NCT04202354

Testing

ARO-HSD Injection, sterile normal saline (0.9% NaCl)

Where

New Zealand

Volunteers

50 people, healthy volunteers welcome

Sponsor

Arrowhead Pharmaceuticals